Anti-tumor effect of cimetidine via inhibiting angiogenesis factors in N-butyl-N-(4-hydroxybutyl) nitrosamine-induced mouse and rat bladder carcinogenesis

Oncology Reports

Volumn 22, Issue 1, 2009, Pages 23-28

  Chihara, Yoshitomo ^a   Fujimoto, Kiyohide ^a   Miyake, Makito ^a   Hiasa, Yoshio ^b   Hirao, Yoshihiko ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b Pathology Division   (Japan)

Author keywords

Angiogenesis; Animal model; Bladder cancer; Cimetidine

Indexed keywords

ANGIOGENIC FACTOR; CIMETIDINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CARCINOGENESIS; CANCER INHIBITION; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS REGULATION; RAT; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANGIOGENIC PROTEINS; ANIMALS; BUTYLHYDROXYBUTYLNITROSAMINE; CIMETIDINE; DOWN-REGULATION; E-SELECTIN; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED BALB C; NEOPLASM STAGING; RATS; RATS, WISTAR; THYMIDINE PHOSPHORYLASE; TIME FACTORS; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 68249143425     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000401     Document Type: Article

References (24)

1. Matsumoto S: Cimetidine and survival with colorectal cancer. Lancet 346: 115, 1995.
2. Morris DL and Adams WJ: Cimetidine and colorectal cancer-old drug, new use? Nat Med 1: 1243-1244, 1995.
3. Sagaster P, Micksche M, Flamm J and Ludwig H: Randomized study using IFN-alpha versus IFN-alpha plus coumarin and cimetidine for treatment of advanced renal cell cancer. Ann Oncol 6: 999-1003, 1995.
4. Lawson JA, Adams WJ and Morris DL: Ranitidine and cimetidine differ in their in vitro and in vivo effects on human colonic cancer growth. Br J Cancer 73: 872-876, 1996.
5. Hahm KB, Kim WH, Lee SI, Kang JK and Park IS: Comparison of immunomodulative effects of the histamine-2 receptor antagonists cimetidine, ranitidine, and famotidine on peripheral blood mononuclear cells in gastric cancer patients. Scand J Gastroenterol 30: 265-271, 1995.
6. Natori T, Sata M, Nagai R and Makuuchi M: Cimetidine inhibits angiogenesis and suppresses tumor growth. Biomed Pharmacother 59: 56-60, 2005.
7. Tomita K, Izumi K and Okabe S: Roxatidine- and cimetidine-induced angiogenesis inhibition suppresses growth of colon cancer implants in syngeneic mice. J Pharmacol Sci 93: 321-330, 2003.
8. Kubota T, Fujiwara H, Ueda Y, et al: Cimetidine modulates the antigen presenting capacity of dendritic cells from colorectal cancer patients. Br J Cancer 86: 1257-1261, 2002.
9. Takahashi K, Tanaka S, Furuta K and Ichikawa A: Histamine H(2) receptor-mediated modulation of local cytokine expression in a mouse experimental tumor model. Biochem Biophys Res Commun 297: 1205-1210, 2002.
10. Kobayashi K, Matsumoto S, Morishima T, Kawabe T and Okamoto T: Cimetidine inhibits cancer cell adhesion to endothelial cells and prevents metastasis by blocking E-selectin expression. Cancer Res 60: 3978-3984, 2000.
11. Fujimoto K, Matsumura Y, Tani Y, Ozono S, Hirao Y and Okajima E: Tissue levels of pyrimidine nucleoside phosphorylase activity in human and rodent bladder cancer and normal bladder tissue. Int J Urol 14: 754-759, 2007.
12. Brown NS, Jones A, Fujiyama C, Harris AL and Bicknell R: Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors. Cancer Res 60: 6298-6232, 2000.
13. Nadaoka J, Horikawa Y, Saito M, et al: Prognostic significance of HIF-1 alpha polymorphisms in transitional cell carcinoma of the bladder. Int J Cancer 122: 1297-1302, 2008.
14. Wakui S, Furusato M, Sasaki S, Muto T, Takahashi H, Masaoka T and Ushigome S: Expression of vascular endothelial growth factor in N-butyl-N-(4-hydroxybutyl)nitrosamine-induced rat bladder carcinogenesis. Vet Pathol 36: 111-116, 1999.
15. Adams WJ, Lawson JA, Nicholson SE, Cook TA and Morris DL: The growth of carcinogen-induced colon cancer in rats is inhibited by cimetidine. Eur J Surg Oncol 19: 332-335,1993.
16. Gifford RRM, Ferfuson RM and Voss BV: Cimetidine reduction of tumor formation in mice. Lancet 1: 638-640, 1981.
17. Chihara Y, Sugano K, Kobayashi Y, et al: Loss of bloodgroup A antigen expression in bladder cancer caused by allelic loss and/or methylation of the ABO gene. Lab Invest 85: 895-907, 2005.
18. Dimitroff CJ, Descheny L, Trujillo N, et al: Identification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic prostate tumor cells. Cancer Res 65: 5750-5760, 2005.
19. Arima J, Imazono Y, Takebayashi Y, et al: Expression of thymidine phosphorylase as an indicator of poor prognosis for patients with transitional cell carcinoma of the bladder. Cancer 88: 1131-1138, 2000.
20. Matsumoto S, Imaeda Y, Umemoto S, Kobayashi K, Suzuki H and Okamoto T: Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells. Br J Cancer 86: 161-167, 2002.
21. Fujimoto K, Hosotani R, Wada M, et al: Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis. Eur J Cancer 34: 1439-1447, 1998.
22. Nonomura N, Nakai Y, Nakayama M, et al: The expression of thymidine phosphorylase is a prognostic predictor for the intravesical recurrence of superficial bladder cancer. Int J Clin Oncol 11: 297-302, 2006.
23. Aoki S, Yamada Y, Nakamura K, Taki T, Tobiume M and Honda N: Thymidine phosphorylase expression as a prognostic marker for predicting recurrence in primary superficial bladder cancer. Oncol Rep 16: 279-284, 2006.
24. Toi M, Inada K, Hoshina S, Suzuki H, Kondo S and Tominaga T: Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer. Clin Cancer Res 9: 961-964, 1995.